Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
December 22, 2021updated 07 Jan 2022 6:15am

More treatment options are needed for paediatric eosinophilic esophagitis

There are currently no late-stage pipeline agents for eosinophilic esophagitis being studied in paediatric populations.

By GlobalData Healthcare

The eosinophilic esophagitis (EoE) therapeutics market has considerable unmet needs; notably, there will be limited clinical developments for pediatric patients in the future. Last year, the US had 1,170,618 lifetime diagnosed prevalent cases of EoE, including 139,440 paediatric cases (aged 11 years and younger) and 1,031,178 adolescent and adult cases (aged 12 years and older).

EoE occurs in children and adults, with symptoms often non-specific and dependent on the age of onset. EoE symptoms in children include difficulty feeding, difficulty eating, vomiting, abdominal pain, decrease in appetite, difficulty swallowing (dysphagia), food impaction and a failure to thrive. In adolescents and adults, EoE symptoms appear as dysphagia, food impaction, chest pain that is often centrally located and does not respond to antacids, and backflow of undigested food (regurgitation).

At present, paediatric patients receive off-label proton pump inhibitors, steroids and dietary therapy similar to adolescents and adults. Unlike adolescents and adults, however, late-stage pipeline agents for EoE are not being studied in paediatric populations, which suggests that they will not be eligible to receive them. Figure 1 illustrates the six EoE pipeline agents currently in Phase III development in the US.

Of the six pipeline agents in late-stage development, Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) is the only pipeline agent being studied in Phase III for a younger population aged 1–11 years. Although Dupixent is expected to be the first marketed drug for paediatrics, the drug is anticipated to target a small subgroup of patients who do not respond to other therapies, rather than being a first-line therapy.

Key opinion leaders interviewed by GlobalData strongly encouraged the initiation of clinical trials for paediatric EoE patients and suggested easing the inclusion and exclusion criteria to improve enrolling paediatric cases in clinical trials. In addition, last September, the US Food and Drug Administration (FDA) finalised guidance to assist sponsors in the clinical development of drugs for the treatment of EoE. Specifically, this guidance addresses the FDA’s current thinking regarding clinical trials and development programs for EoE drugs, including recommendations for the necessary attributes of patients for enrollment, trial designs, efficacy considerations, safety assessments and paediatric-specific considerations. The guidance also recommended that the adolescent trials should be followed by trials for paediatric patients aged younger than 12 years, guided by safety and efficacy data from adolescent and adult trials.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

GlobalData expects that limited treatment options for paediatric patients will remain a significant unmet need in the EoE space. As a result, the opportunity remains for developers to expand the current clinical studies to paediatric populations.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU